Nevertheless, targeted therapies (e.g., EGFR inhibitors for EGFR-mutated LC) have consistently demonstrated meaningful clinical benefit in patients with oncogene-addicted tumors [26]. Here, EGFR is linked to laryngotracheoesophageal cleft.